Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Shares Outstanding (Weighted Average) (2023 - 2025)

Historic Shares Outstanding (Weighted Average) for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $88.0 million.

  • Immunome's Shares Outstanding (Weighted Average) rose 4609.65% to $88.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.0 million, marking a year-over-year increase of 4609.65%. This contributed to the annual value of $58.6 million for FY2024, which is 19550.73% up from last year.
  • Immunome's Shares Outstanding (Weighted Average) amounted to $88.0 million in Q3 2025, which was up 4609.65% from $87.0 million recorded in Q2 2025.
  • Immunome's 5-year Shares Outstanding (Weighted Average) high stood at $88.0 million for Q3 2025, and its period low was $12.2 million during Q1 2023.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $49.2 million, with a median of $58.6 million in 2024.
  • In the last 5 years, Immunome's Shares Outstanding (Weighted Average) soared by 39339.19% in 2024 and then soared by 4517.11% in 2025.
  • Quarter analysis of 3 years shows Immunome's Shares Outstanding (Weighted Average) stood at $19.8 million in 2023, then soared by 195.51% to $58.6 million in 2024, then skyrocketed by 50.0% to $88.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $88.0 million in Q3 2025, compared to $87.0 million in Q2 2025 and $79.4 million in Q1 2025.